TAT2-a | Glycogen2-b | GR2-c | CBG2-c | |
---|---|---|---|---|
ALDO | 1.1 ± 0.1 | 1.5 ± 0.2 | 74.6 ± 7.6 | 905.5 ± 50.1 |
DOC | 2.8 ± 0.3 | 3.1 ± 0.6 | 6.9 ± 2.1 | 14.8 ± 3.5 |
CORT | 7.4 ± 0.6 | 5.7 ± 0.5 | 1.0 ± 0.2 | 1.0 ± 0.1 |
PROG | 2.0 ± 0.5 | 0.9 ± 0.1 | 6.2 ± 0.5 | 289.1 ± 9.9 |
11-OP | 1.0 ± 0.1 | 1.4 ± 0.2 | >2000 | >2000 |
6-OP | 1.0 ± 0.1 | 0.8 ± 0.3 | >2000 | >2000 |
↵2-a Isolated hepatocytes from ADX rats were incubated with 100 nM steroid, and the induction of tyrosine amino transferase (TAT) activity was measured. Results represent fold induction (mean ± S.E. of three experiments performed in duplicate) with respect to the control incubated with vehicle alone (4.0 ± 1.0 μmol of tyrosine × 10−6 cells × min−1).
↵2-b Glycogen was obtained from the liver of ADX rats after acute treatment with the indicated steroid. Values are expressed as a fold increase (mean ± S.E. for eight rats per group) with respect to controls injected with vehicle (9.1 ± 1.2 mg of glycogen/g of liver).
↵2-c RBAs were calculated from competition curves between the steroid and 5.0 nM [3H]CORT. Thymocyte cytosol homogenized in TEGI buffer was used as a source of GR. Rat plasma was fractionated with solid ammonium sulfate at 30 to 60% of saturation, dissolved in TEGI buffer afterward, dialyzed, and used as a source of albumin-free CBG. Values are expressed in nanomolar and represent the mean ± S.E. of three independent experiments, each one performed in quintuplicate.